Medication info
Sebaco Tablet 5/40 Milligrams

Sebaco Tablet 5/40 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Ajou Pharmaceutical Co., Ltd.
Appearance
Pale yellow round film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201901355 · Approved 2019.03.06 · Insurance code 654005290

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use caution when administering this medicine to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should have their blood pressure and renal function closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this medicine, under Precautions for Use.) ∘Older adults: Treatment is generally started at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
Child dose
∘Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Ajou Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication effectively lowers blood pressure in patients with essential hypertension whose blood pressure is not sufficiently controlled by monotherapy with amlodipine or olmesartan medoxomil.

How to take

Adult dose

Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use caution when administering this medicine to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should have their blood pressure and renal function closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this medicine, under Precautions for Use.) ∘Older adults: Treatment is generally started at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.

Child dose

∘Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This drug may cause serious harm to the fetus and neonates if taken during the second and third trimester of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Those who have allergies to the active ingredients or similar substances, are pregnant or breastfeeding, have severe liver disorders or aortic stenosis, or are patients with biliary obstruction, undergoing kidney dialysis, in a state of shock, or certain diabetic patients should not take this medication. Patients with hypotension due to lack of fluid or salt, patients with vasodilation, those with severe obstructive coronary artery disease, patients with congestive heart failure, and those with impaired kidney or liver function should use this drug cautiously and under a doctor's supervision. Side effects such as dizziness, headache, hypotension, edema, dyspepsia, and rash may occur during treatment; if symptoms are severe, consult a physician. This drug may interact with certain other medications, so you must inform your doctor or pharmacist if you are taking other medications. Women who are pregnant or planning to become pregnant are advised to choose a safer alternative therapy instead of this drug, and to stop taking it immediately upon confirmation of pregnancy. If breastfeeding, consult a physician regarding whether to continue nursing or discontinue the medication, as this drug may be passed into breast milk. Safety and efficacy have not been established in children under 18, so it is not recommended. Elderly patients may have decreased kidney or liver function; starting with a lower dose and careful monitoring is necessary. In cases of overdose, severe hypotension or vasodilation may occur, requiring immediate emergency treatment. This drug should be stored in a place protected from direct sunlight and moisture, out of reach of children.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • sensory abnormalities
  • diminished sensation
  • syncope
Show 81 more
  • vertigo
  • palpitations
  • tachycardia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle rigidity
  • limb pain
  • lumbago
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyltransferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • worsening of cerebral infarction
  • gum bleeding
  • positional dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • rhinorrhea
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastritis
  • shingles
  • diplopia
  • insomnia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vessel edema
  • rhabdomyolysis
  • acute renal failure
  • alopecia
  • itching
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • non-cardiogenic pulmonary edema
  • tachycardia
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a tightly closed container. It is advisable to keep the storage temperature between 1 degree and 30 degrees Celsius at room temperature. This will help maintain the drug's efficacy and safety over time.

Appearance and packaging

Appearance

Pale yellow round film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.